vs
Side-by-side financial comparison of PARK NATIONAL CORP (PRK) and Protagonist Therapeutics, Inc (PTGX). Click either name above to swap in a different company.
Protagonist Therapeutics, Inc is the larger business by last-quarter revenue ($170.6M vs $168.3M, roughly 1.0× PARK NATIONAL CORP). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs 25.3%, a 51.8% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs 2.2%). PARK NATIONAL CORP produced more free cash flow last quarter ($191.9M vs $182.8M).
National Retail Systems, Inc. (NRS) includes Keystone Freight Corp. & National Retail Transportation, Inc. (NRT). NRS is an asset based 3PL founded in 1952. It is headquartered in Lyndhurst, New Jersey, United States.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
PRK vs PTGX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $168.3M | $170.6M |
| Net Profit | $42.6M | $131.7M |
| Gross Margin | — | — |
| Operating Margin | — | 74.3% |
| Net Margin | 25.3% | 77.2% |
| Revenue YoY | 2.2% | 184.4% |
| Net Profit YoY | 10.4% | 381.7% |
| EPS (diluted) | $2.62 | $2.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.3M | — | ||
| Q3 25 | $169.5M | — | ||
| Q2 25 | $168.7M | — | ||
| Q1 25 | $157.9M | — | ||
| Q4 24 | $164.7M | $170.6M | ||
| Q3 24 | $170.3M | — | ||
| Q2 24 | $157.7M | — | ||
| Q1 24 | $152.8M | $255.0M |
| Q4 25 | $42.6M | — | ||
| Q3 25 | $47.2M | — | ||
| Q2 25 | $48.1M | — | ||
| Q1 25 | $42.2M | — | ||
| Q4 24 | $38.6M | $131.7M | ||
| Q3 24 | $38.2M | — | ||
| Q2 24 | $39.4M | — | ||
| Q1 24 | $35.2M | $207.3M |
| Q4 25 | — | — | ||
| Q3 25 | 34.3% | — | ||
| Q2 25 | 35.2% | — | ||
| Q1 25 | 32.4% | — | ||
| Q4 24 | — | 74.3% | ||
| Q3 24 | 27.4% | — | ||
| Q2 24 | 30.6% | — | ||
| Q1 24 | 27.8% | 80.9% |
| Q4 25 | 25.3% | — | ||
| Q3 25 | 27.8% | — | ||
| Q2 25 | 28.5% | — | ||
| Q1 25 | 26.7% | — | ||
| Q4 24 | 23.5% | 77.2% | ||
| Q3 24 | 22.4% | — | ||
| Q2 24 | 25.0% | — | ||
| Q1 24 | 23.0% | 81.3% |
| Q4 25 | $2.62 | — | ||
| Q3 25 | $2.92 | — | ||
| Q2 25 | $2.97 | — | ||
| Q1 25 | $2.60 | — | ||
| Q4 24 | $2.38 | $2.01 | ||
| Q3 24 | $2.35 | — | ||
| Q2 24 | $2.42 | — | ||
| Q1 24 | $2.17 | $3.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $233.5M | $418.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $675.3M |
| Total Assets | $9.8B | $744.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $233.5M | — | ||
| Q3 25 | $218.9M | — | ||
| Q2 25 | $193.1M | — | ||
| Q1 25 | $237.6M | — | ||
| Q4 24 | $160.6M | $418.9M | ||
| Q3 24 | $201.7M | — | ||
| Q2 24 | $261.5M | — | ||
| Q1 24 | $306.1M | $322.6M |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.2B | $675.3M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | $560.4M |
| Q4 25 | $9.8B | — | ||
| Q3 25 | $9.9B | — | ||
| Q2 25 | $9.9B | — | ||
| Q1 25 | $9.9B | — | ||
| Q4 24 | $9.8B | $744.7M | ||
| Q3 24 | $9.9B | — | ||
| Q2 24 | $9.9B | — | ||
| Q1 24 | $9.9B | $629.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $198.3M | $184.2M |
| Free Cash FlowOCF − Capex | $191.9M | $182.8M |
| FCF MarginFCF / Revenue | 114.1% | 107.1% |
| Capex IntensityCapex / Revenue | 3.8% | 0.8% |
| Cash ConversionOCF / Net Profit | 4.65× | 1.40× |
| TTM Free Cash FlowTrailing 4 quarters | $328.2M | $101.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $198.3M | — | ||
| Q3 25 | $52.6M | — | ||
| Q2 25 | $49.7M | — | ||
| Q1 25 | $37.9M | — | ||
| Q4 24 | $178.8M | $184.2M | ||
| Q3 24 | $43.8M | — | ||
| Q2 24 | $50.9M | — | ||
| Q1 24 | $35.0M | $-27.4M |
| Q4 25 | $191.9M | — | ||
| Q3 25 | $51.1M | — | ||
| Q2 25 | $48.4M | — | ||
| Q1 25 | $36.8M | — | ||
| Q4 24 | $169.7M | $182.8M | ||
| Q3 24 | $41.7M | — | ||
| Q2 24 | $49.0M | — | ||
| Q1 24 | $31.9M | $-27.7M |
| Q4 25 | 114.1% | — | ||
| Q3 25 | 30.1% | — | ||
| Q2 25 | 28.7% | — | ||
| Q1 25 | 23.3% | — | ||
| Q4 24 | 103.0% | 107.1% | ||
| Q3 24 | 24.5% | — | ||
| Q2 24 | 31.1% | — | ||
| Q1 24 | 20.8% | -10.9% |
| Q4 25 | 3.8% | — | ||
| Q3 25 | 0.9% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 5.6% | 0.8% | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | 2.1% | 0.1% |
| Q4 25 | 4.65× | — | ||
| Q3 25 | 1.11× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 0.90× | — | ||
| Q4 24 | 4.63× | 1.40× | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | 0.99× | -0.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
